The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival

Department of Surgery and the Center on Outcomes Research and Education, NorthShore University Health System, Evanston, and Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
American journal of surgery (Impact Factor: 2.29). 03/2009; 197(3):403-7. DOI: 10.1016/j.amjsurg.2008.11.014
Source: PubMed


The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers.
Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002.
There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002).
HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.

Download full-text


Available from: David Winchester, Nov 04, 2014
13 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review summarizes the current state of knowledge on Lepidium meyenii (maca), a cruciferous plant (Brassicaceae family) which is cultivated exclusively at an altitude of 4,000-4,500 m in the Peruvian Central Andes. Maca is traditionally used for its nutritional and presumed medicinal properties. Over the past 20 years, interest in maca has increased in many parts of the world, and since 2005 maca is considered one of the seven Peruvian flag products. Maca is exported as powder, capsules, pills, flour, liquor, and extracts. There are different types of maca with differ-ent colors ranging from white to black. We have studied the pharmacological effects of 3 types; yellow, black, and red maca. Evidence from experimental studies indicates effects of maca on nutrition, fertility, memory, and mood. Black maca has better effects on sperm production than yellow maca which has only moderate effects. Red maca, however, has no effect on sperm production. However, red maca has been shown to reduce prostate size in rats in which prostate hyperplasia had been induced with testosterone enanthate; yellow maca has shown moderate effects here, whereas black maca has not shown any effects. Randomized clinical trials have shown that maca has favorable effects on energy and mood, may decrease anxiety and improve sexual desire. Maca has also been shown to improve sperm production, sperm motility, and semen volume. Serum levels of testosterone, estradiol, LH, FSH, and prolactin were not affected. The exact mechanisms of action are still unclear, but so far research clearly indicates that various bioactive constituents contribute to the clinical effects reported.
    Forschende Komplementärmedizin / Research in Complementary Medicine 12/2009; 16(6):373-80. DOI:10.1159/000264618 · 1.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Exposure to postmenopausal hormone therapy (HT) may affect the stage, histological type, and hormone receptor (HR) status of invasive breast cancer at the time of diagnosis. One thousand six hundred eighty-four women with newly diagnosed first invasive breast cancer were recruited to the "MBF Foundation Health and Wellbeing after Breast Cancer Study." Women using systemic HT estrogen (E) or E combined with progesterone (P) at the time of diagnosis of breast cancer were compared with those not using HT. Breast cancer tumor data were obtained from the Victorian Cancer Registry. Regression analysis was used to determine the associations between HT use or not at the time of diagnosis and tumor histology (ductal vs lobular), stage (I vs II, III, IV), HR status (ER+ or PR+ or both vs ER- or PR-). Of 1,377 women included in the analysis, 226 (16%) were using HT at the time of diagnosis. Of HT users, 20.4% had lobular breast cancer, 50% were stage I, and 85.8% had HR-positive tumors. Of non-users, 13.6% had lobular breast cancer, 48.2% were stage I, and 82.4% had HR-positive tumors. Use of systemic HT was associated with increased odds of having lobular compared with ductal breast cancer (OR = 1.75, 95% CI = 1.14-2.69, p = 0.01). There were no associations between HT use and either breast cancer stage or HR status. Women using systemic HT at the time of diagnosis were more likely to have lobular rather than ductal breast cancer compared with women not on HT.
    Hormones and Cancer 04/2010; 1(2):93-9. DOI:10.1007/s12672-010-0011-0 · 0.02 Impact Factor
  • American journal of surgery 05/2010; 199(5):723. DOI:10.1016/j.amjsurg.2009.03.029 · 2.29 Impact Factor
Show more